(Boursier.com) — Boehringer Ingelheim and OSE Immunotherapeutics announce a new milestone in their license and collaboration agreement whereby Boehringer Ingelheim has acquired the exclusive rights to BI 765063, a first-in-class SIRP inhibitor? on the SIRP?/CD47 myeloid axis. The first patient was treated in the Phase 1 expansion led by Boehringer Ingelheim in difficult-to-treat advanced cancers.
This international Phase 1 clinical study aims to evaluate BI 765063 in patients with metastatic or recurrent hepatocellular carcinoma (HCC), or head and neck squamous cell carcinoma (CCSTC).
Dominique Costantini, CEO of OSE Immunotherapeutics, comments: “We thank Boehringer Ingelheim for this important milestone which demonstrates our partner’s commitment and confidence in the potential of BI 765063 to target myeloid cells. In the As part of our partnership, the product is now being evaluated in two new indications in oncology and in highly disabling tumor types, namely hepatocellular carcinoma and head and neck cancer.The payment associated with this step will strengthen the cash from OSE to advance the development of our first-in-class product portfolio”.
In parallel, BI 765063 is being evaluated in Europe in combination with ezabenlimab in a Phase 1 expansion study in patients with advanced colorectal cancer and advanced endometrial cancer with stable microsatellites, relapsed after standard therapy and n who had not previously received anti-PD-L1 inhibitors. The study is being conducted by OSE Immunotherapeutics.
©2022 Boursier.com